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Introduction
In recent years, steps have been undertaken to increase the avail-
ability and transparency of health technology pricing and reim-
bursement information across countries. For instance, the
Pharmaceutical Pricing and Reimbursement Information project
commissioned by the European Commission provided a frame-
work for comparability of pharmaceutical pricing and reim-
bursement data and policies, developed a core set of indicators,
and conducted comparative analyses based on country proﬁles
[1]. The Organisation for Economic Co-operation and Develop-
ment carried out a similar project that generated a taxonomy of
pharmaceutical pricing and reimbursement policies, and ana-
lyzed the cross-national impact of these policies [2]. Both initia-
tives also focused on the role which health technology assessment
(HTA) and economic evaluation play in informing pricing and
reimbursement policies.
The aim of this article is to justify the need for HTA and
economic evaluation across jurisdictions. The term “jurisdic-
tion” is used to indicate any setting where a local HTA or
economic evaluation is carried out. This may refer to a country
or a region within a country, but could also relate to a speciﬁc
health-care payer.
Pricing and Reimbursement
To inform pricing and reimbursement decisions, an increasing
number of jurisdictions require companies to carry out a HTA or
economic evaluation with a view to demonstrating the value of a
new health technology. For instance, the Pharmaceutical Beneﬁts
Advisory Scheme in Australia and the provincial government of
Ontario (Canada) consider the cost-effectiveness of medicines
when assessing a reimbursement application [3]. Furthermore,
jurisdictions tend to move from a one-off assessment at the time
of the initial application to a system of temporary or conditional
pricing and reimbursement of health technologies requiring mul-
tiple assessments. In Belgium, for instance, the decision to reim-
burse medicines with an added therapeutic value depends on the
cost-effectiveness and budget impact of the medicine at the time
of the reimbursement application, and on such evidence after
3 years after the admission to the reimbursement system. This
means that there is not only a requirement for HTA and eco-
nomic evaluation in an increasing number of jurisdictions, but
also a requirement that such evidence is provided on a periodical
basis.
The HTA and economic evaluation across jurisdictions could
contribute to a more cost-effective use of resources with a view to
informing pricing and reimbursement decisions. Such an
approach would support jurisdictions with restricted resources
or limited expertise in conducting and evaluating such exercises.
This tends to apply to Eastern European countries who are
building up their experience in HTA and economic evaluation
[4]. Furthermore, the increasing complexity of diseases and
health technologies implies that jurisdictions do not always have
the necessary expertise to assess pricing and reimbursement
applications. Take, for example, the recent vaccines that aim to
prevent human papillomavirus strains associated with the devel-
opment of cervical cancer. Since 2007, publicly funded vaccina-
tion programms have been launched in a number of European
countries, including Belgium, Denmark, France, Germany, Italy,
Greece, Norway, Romania, and the United Kingdom. Countries
facing a reimbursement application could draw on the experience
and expertise of countries that have already conducted a HTA
and economic evaluation of human papillomavirus vaccines. It
follows that authorities in different jurisdictions may wish to
specialize in different disease areas. Such an approach could
involve some form of mutual recognition, even though a juris-
diction would retain the right to accept or reject an evaluation
performed in another jurisdiction [4].
Pricing and reimbursement of orphan medicines could beneﬁt
from HTA and economic evaluation across jurisdictions. The
European Commission deﬁnes an orphan medicine as a product
that is intended for the diagnosis, prevention or treatment of a
life-threatening or chronically debilitating condition affecting not
more than 5 in 10,000 persons in the European Union [5].
Because of the low prevalence, it may prove difﬁcult to document
costs and effectiveness of an orphan medicine in a sufﬁcient
number of patients. In this area, there is a need for studies across
jurisdictions. If such studies yield patient data, including data on
patients from the jurisdiction of interest, a number of analytic
techniques can be used to calculate the cost-effectiveness of an
orphan medicine for that jurisdiction [6]. Such an approach
seems not only to be particularly suited to the evaluation of
orphan medicines, but is also relevant to other health technolo-
gies where effectiveness data are derived from large, multiloca-
tion trials that also gather data on costs.
Guidelines
Guidelines have been implemented around the world that
provide a guide for designing and conducting HTAs and eco-
nomic evaluations to be included in pricing and reimbursement
applications [7]. Guidelines vary from jurisdiction to jurisdiction,
Address correspondence to: Steven Simoens, Research Centre for Pharma-
ceutical Care and Pharmaco-economics, Faculty of Pharmaceutical
Sciences, Katholieke Universiteit Leuven, Onderwijs en Navorsing
2, Herestraat 49, PO Box 521, 3000 Leuven, Belgium. E-mail:
steven.simoens@pharm.kuleuven.be
10.1111/j.1524-4733.2010.00756.x
Volume 13 • Number 6 • 2010
V A L U E I N H E A LT H
© 2010, International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 1098-3015/10/857 857–861 857
reﬂecting differences in the availability of health-care resources,
clinical practice patterns, prices, the organization and ﬁnancing
of health-care systems, and health technology decision-making
processes [8]. This implies that analyses increasingly need to be
customized to a speciﬁc jurisdiction. Such jurisdiction-speciﬁc
analyses may not only inform the local decision-making process,
but may also be used for benchmarking purposes in other juris-
dictions. Nevertheless, this customization process raises costs of
gaining pricing and reimbursement approval. As a result, com-
panies sometimes develop global decision-analytic models that
are speciﬁcally designed to be adapted from jurisdiction to juris-
diction. Although guidelines differ between jurisdictions,
common elements in the guidelines exist between some jurisdic-
tions, making it possible to exchange relevant information. For
instance, pharmacoeconomic guidelines in Belgium and France
are similar in terms of the choice of comparator, time horizon,
source of costs, use of modeling, systematic review of existing
clinical and economic studies, preference for ﬁnal outcome mea-
sures, discounting, subgroup analysis, and sensitivity analysis [7].
A move toward more uniform evidence requirements between
jurisdictions would facilitate the process of generating data
during the research and development process, and would
decrease costs of gaining pricing and reimbursement approval.
Jurisdiction-to-jurisdiction adaptations of HTAs and eco-
nomic evaluations raise the issues of generalizability and trans-
ferability. An analysis is generalizable if it can be applied without
adjustment to another jurisdiction, whereas an analysis is trans-
ferable if it can be adapted to apply to another jurisdiction [6].
Adapting research conducted in one jurisdiction to another juris-
diction entails various degrees of complexity. Recently, an adap-
tation scale has been proposed ranging from no adaptation
(transfer research), simple adaptation (e.g., perform exchange
rate conversion of costs), more complex adaptation (replace all
data inputs with appropriate data from the jurisdiction of inter-
est, including costs, treatment patterns, survival estimates, and
utility values), sophisticated adaptation (replace all data inputs
and restructure the analytical framework), to impossible adapta-
tion (conduct new research speciﬁc to the jurisdiction) [9]. Fur-
thermore, the ISPOR Task Force on Transferability of Economic
evaluations has developed good research practices for dealing
with aspects of transferability [6]. These practices consider ana-
lytic strategies based on the analysis of individual patient data
gathered in clinical trials, and strategies based on decision-
analytic modeling. The degree of adaptation required depends on
a number of issues, including the objectives of the analysis,
availability of data, methodological rigor, time and budgetary
constraints [9].
EUnetHTA
Since the 1990s, the European Commission has launched mul-
tiple projects to foster European collaboration in HTA, including
EUR-ASSESS (1994–1997), Health Technology Assessment
Europe (HTA Europe, 1997–1999), and The European Collabo-
ration for Health Technology Assessment/The European Col-
laboration for Assessment of Health Interventions (ECHTA/
ECAHI, 1999–2001).
In 2004, the European Commission’s High Level Group on
Health Services and Medical Care concluded that HTA has
become a political priority and that there is an urgent need for
establishing a sustainable European network for HTA [10]. The
recent European Network for Health Technology Assessment
(EUnetHTA, 2006–2008) aimed to strengthen the link between
HTA and health-care policymaking in the European Union, and
to connect public national HTA agencies, research institutions,
and health ministries with a view to enable the exchange of
information and to support policy decisions by Member States
[11]. EUnetHTA involved 32 countries and 63 partner organiza-
tions. The project consisted of eight work packages: coordina-
tion, communication, evaluation of the project, a core model for
HTA, adapting existing HTAs, transferability to health policy,
emerging new technologies, and capacity building.
Among other things in the communication work package, the
EUnetHTA project set up a clearinghouse, i.e., a shared working
space where countries can exchange information. Take, for
example, a HTA that involves a systematic review of the effec-
tiveness evidence. One jurisdiction could carry out the systematic
review and use the clearinghouse to make the review accessible to
other jurisdictions.
The fourth EUnetHTA work package developed a core model
for HTA [12]. A standardized structure for HTA serves to facili-
tate transparent presentation of information, transnational use of
that information, and effective collaboration between partner
organizations in different countries. The core model consists of a
number of domains (i.e., health problem and current use of
technology, technical characteristics, safety, clinical effectiveness,
costs and economic evaluation, ethical analysis, organizational
aspects, social aspects, legal aspects), each of which is subdivided
into assessment elements. In total, 163 assessment elements were
identiﬁed in the core model based on consensus. The core model
for HTA enables the distributed production of HTA: the research
for different domains can be carried out by separate partner
organizations and countries can select those assessment elements
and domains that they deem to be relevant for their national
decision-making processes. To date, a core HTA has been con-
ducted for drug eluting stents and for multislice computed
tomography coronary angiography.
The European collaboration around HTA is set to continue,
given that HTA was listed as a high priority in the European
Union Health Programme 2008–2013.
Conclusions
This article has argued in favor of HTA and economic evaluation
across jurisdictions with a view to informing pricing and reim-
bursement policies. The development of a core model for HTA
also shows that an approach across jurisdictions can offer sufﬁ-
cient ﬂexibility to take into account jurisdiction-speciﬁc guide-
lines. In the same way that society needs to allocate scarce
resources in a cost-effective way, an approach across jurisdictions
may help to ensure that the process of conducting HTA and
economic evaluation is also cost-effective.
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Introduction
Health technology assessment (HTA) is now an established input
to health-care decision-making in many countries. For example,
the International Network of Agencies for Health Technology
Assessment (INAHTA) has members from 24 countries including
North and Latin America, Europe, Asia, Australia and New
Zealand, and provides a “forum for the identiﬁcation and pursuit
of interests common to health technology assessment agencies”
[1]. Organizations such as INAHTA have come about because
HTA is based upon a general set of principles and involves the
study of the medical, social, ethical, and economic implications
of the development, diffusion, and use of a health technology. In
this article, arguments are presented to illustrate that despite
these common principles, the process of HTA, and more particu-
larly its economic evaluation component, needs to take a
national approach toward evaluation. These arguments are not
against the learning of lessons from work conducted in other
jurisdictions, but rather that the differences between countries
means that the results of an economic evaluation conducted in
one setting might not be applicable to another and as a conse-
quence, country-speciﬁc evaluations are needed that reﬂect the
needs of the decision-makers in that country.
Generalizability andTransferability
It is argued by Simoens that the results of economic evaluation are
generalizable from one setting to another if, withoutmodiﬁcation,
they are believed to be applicable to that setting. For this to
happen, not only do the data inputs to the economic evaluation
have to be applicable but also the way in which they relate to each
other in the original setting has to be consistent with the way in
which they should be brought together in the new setting. Differ-
ences in the culture, organization of health care and other sectors
of the economy may all change the patterns of care between
settings and hence change the way in which costs and beneﬁts are
accrued. If patterns of care and other factors affecting the delivery
of health care are similar, it may be possible to repeat an analysis
using local data on costs, utilities, etc. This was an approach
adopted by Coyle et al. who adapted a UK model comparing the
cost-effectiveness ofminimally invasive total hip replacementwith
standard total hip replacement to a Canadian setting [2]. In this
analysis, Canadian data on costs and utilities were substituted for
UK data. Underlying data on the epidemiology/natural history of
people after total hip replacement and on the relative effectiveness
of the two procedures were assumed to be same as that used in the
UK model. Such an approach was thought acceptable as the
underlying patterns of carewere believed to be similar between the
two countries. In this particular situation, the policy conclusion
with respect to the use of minimally invasive total hip replacement
was similar for both the UK and Canada—primarily because of
the absence of evidence on relative effectiveness. In other situa-
tions, it is possible that a different policy conclusion might be
drawn. For example, in an economic evaluation of the cost-
effectiveness of bisphosphonates to prevent hip fractures, it was
found that bisphosphonates were likely to be cost-effective in
Ottawa but not in Texas [3]. One of the reasons for this was that
the underlying risk of falling, and hence the risk of hip fractures,
was lower in Texas than in Ottawa. This meant that the capacity
to beneﬁt from bisphosphonates was much lower in Texas than in
Ottawa.What these examples illustrate is that, as Simoens argues,
it may be possible to make economic evaluations transferable
between settings.
In such a situation, international cooperation may be desir-
able and indeed the hip replacement example was completed
from start to ﬁnish with the express intention of conducting an
evaluation for both the UK and Canada.
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